Effects of Telmisartan Therapy on Metabolic Profiles and Serum High Molecular Weight (HMW)-Adiponectin Level in Japanese Male Hypertensive Subjects with Abdominal Obesity

• Komiya Naoko

  Department of Internal Medicine, Keio University School of Medicine.

• Hirose Hiroshi

  Department of Internal Medicine, Keio University School of Medicine. Health Center, Keio University School of Medicine.

• Kawabe Hiroshi

  Department of Internal Medicine, Keio University School of Medicine. Health Center, Keio University School of Medicine.

• Itoh Hiroshi

  Department of Internal Medicine, Keio University School of Medicine.

• Saito Ikuo

  Department of Internal Medicine, Keio University School of Medicine. Health Center, Keio University School of Medicine.

抄録

Aim: Telmisartan, an angiotensin II receptor blocker (ARB), was reported to have partial peroxisome proliferator-activated receptor gamma (PPARγ) activity in vitro. Also, adipocyte-derived protein adiponectin, especially its high molecular weight (HMW) form, has been reported to have beneficial effects on insulin resistance and atherosclerosis. We investigated the effects of 3-month telmisartan therapy on various metabolic parameters, including serum HMW adiponectin and high-sensitivity C-reactive protein (hs-CRP) levels in male hypertensive subjects with abdominal obesity.<BR>Methods: This study included 19 Japanese male hypertensive subjects, aged 51.2±7.6 (mean±SD) years, and body mass index 27.7±4.1 kg/m². In these subjects, 14 were naive to telmisartan treatment (40.0±15.7 mg daily), and 5 were changed from other ARBs to telmisartan. Serum HMW adiponectin concentration was assayed using HMW-selective ELISA kit.<BR>Results: In all 19 subjects, systolic/diastolic blood pressure (BP) decreased from 153/98 to 134/85 mmHg (p<0.001 for both). Serum HMW-adiponectin level increased from 2.06±0.81 to 2.40±0.96 μg/mL (+16.4%, p=0.017). Body weight, glucose, insulin, lipids and hs-CRP did not change during the study period, and there were no adverse effects in any subject. In the newly administered group (n=14), the results were almost the same: BP decreased from 155/98 to 134/84 mmHg (p=0.0015 for both), and serum HMW-adiponectin level increased from 2.07±0.68 to 2.39±0.99 μg/mL (+15.5%, p=0.089).<BR>Conclusion: These data suggest that telmisartan therapy is efficient for controlling BP, and may exert beneficial effects on HMW adiponectin in male hypertensive subjects with abdominal obesity.

収録刊行物

• Ｊｏｕｒｎａｌ　ｏｆ　Ａｔｈｅｒｏｓｃｌｅｒｏｓｉｓ　ａｎｄ　Ｔｈｒｏｍｂｏｓｉｓ

  Ｊｏｕｒｎａｌ　ｏｆ　Ａｔｈｅｒｏｓｃｌｅｒｏｓｉｓ　ａｎｄ　Ｔｈｒｏｍｂｏｓｉｓ 16 (2), 137-142, 2009

  一般社団法人 日本動脈硬化学会

キーワード

• Obesity
• Insulin resistance
• High-sensitivity C-reactive protein
• PPAR gamma

詳細情報

• CRID: 1390282679409534080
• NII論文ID: 10025765186
• NII論文ID: 130004444264
• NII書誌ID: AA11018976
• DOI: 10.5551/jat.e588
• ISSN: 18803873
• ISSN: 13403478
• Web Site: https://search.jamas.or.jp/link/ui/2009308067
• 本文言語コード: en
• データソース種別:
  • JaLC
  • Crossref
  • CiNii Articles
• 抄録ライセンスフラグ: 使用不可